AntaeusREGULATORY DEVELOPMENT
Antaeus Biosciences is pursuing bemitil as a drug. The current $1–2M pre-seed round funds preclinical work toward a candidate decision. It does not fund a supplement launch or establish human efficacy.
Preclinical evidence and an IND-led plan
Safety and efficacy evidence for a defined product and use
Assess whether existing findings can support part of an NDA. Reliance and bridging must be justified.
A fuller original evidence package when the reliance route does not fit.
The company has selected drug development. The NDA pathway requires a product-specific gap assessment. A supplement launch is outside this plan.
01 / COMPANY DECISION
We are pursuing drug development through an IND-led clinical program and an appropriate NDA pathway. We will assess 505(b)(2) reliance on existing evidence with regulatory specialists. No IND or NDA is represented as filed.
02 / DECISION TREE
The selected branch is drug development. After a supported preclinical decision, prepare the quality, safety and clinical package needed for an IND. Then determine whether an NDA can rely in part on existing evidence under 505(b)(2) or needs a fuller applicant-generated package under 505(b)(1). The supplement branch is outside this company plan.
03 / PRESCRIPTION DEVELOPMENT
The drug branch begins with authenticated material, manufacturing information, nonclinical safety and a clinical protocol. A US investigational study that requires an IND cannot begin until the IND is in effect and other required approvals are in place. FDA has an initial 30-day review window; a clinical hold can stop the study.
04 / 505(b)(2)
A 505(b)(2) NDA may rely in part on published studies or certain FDA findings not owned by the applicant. It remains a full approval application. Whether the bemitil literature can support this route, and what bridging work would be required, needs regulatory assessment. Soviet-era use is not a US approval shortcut.
05 / 505(b)(1)
If the available literature cannot support the necessary reliance, an application may need a fuller applicant-generated package under 505(b)(1). Both drug routes require adequate evidence of quality, safety and effectiveness. [REGULATORY GAP ASSESSMENT: fill in].
06 / DIETARY SUPPLEMENT
We are developing a drug, not selling bemitil as a supplement. NDI means new dietary ingredient notification; NDA means new drug application. NDI eligibility, safety notification and lawful supplement claims are separate requirements. A notification is not a substitute for drug approval.
07 / TRADEOFFS
Prescription development can support approved treatment claims if evidence earns approval. It requires clinical development, manufacturing controls and further capital. A supplement route cannot substitute for those requirements. The cost and timing of the selected drug route depend on a product-specific legal and scientific assessment.
08 / TARGET TIMELINE
Months 0–3: leadership, authenticated material and locked thresholds. Months 3–9: molecular profiling, functional heat testing and independent confirmation. The month-nine stop rule applies to failed replication or unacceptable safety. [REGULATORY MILESTONE DATE: fill in]. An IND filing date and a market-launch date are not established.